All Stories

  1. Evaluation of Gradient Concentration Strips for Detection of Terbinafine Resistance in Trichophyton spp.

    Article • Antimicrobial Agents and Chemotherapy, June 2023, ASM Journals

    Dr Eric Dannaoui

  2. Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species

    Article • Journal de Mycologie Médicale, November 2022, Elsevier

    Dr Eric Dannaoui

  3. Aspergillus detection in airways of ICU COVID-19 patients: To treat or not to treat?

    Article • Journal de Mycologie Médicale, August 2022, Elsevier

    Dr Eric Dannaoui

  4. Species Identification and In Vitro Antifungal Susceptibility of Paecilomyces/Purpureocillium Species Isolated from Clinical Respiratory Samples: A Multicenter Study

    Article • Journal of Fungi, June 2022, MDPI AG

    Dr Eric Dannaoui

  5. Evaluation of two commercial kits and two laboratory-developed qPCR assays compared to LAMP for molecular diagnosis of malaria

    Article • Malaria Journal, June 2022, Springer Science + Business Media

    Dr Eric Dannaoui

  6. Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications

    Article • Journal of Antimicrobial Chemotherapy, June 2022, Oxford University Press (OUP)

    Dr Eric Dannaoui

  7. Synergistic In Vitro Interaction of Isavuconazole and Isoquercitrin against Candida glabrata

    Article • Journal of Fungi, May 2022, MDPI AG

    Dr Eric Dannaoui

  8. In Vitro Synergy of Isavuconazole Combined With Colistin Against Common Candida Species

    Article • Frontiers in Cellular and Infection Microbiology, April 2022, Frontiers

    Dr Eric Dannaoui

  9. Recent Developments in the Diagnosis of Mucormycosis

    Article • Journal of Fungi, April 2022, MDPI AG

    Dr Eric Dannaoui

  10. Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis – Authors' reply

    Article • The Lancet Respiratory Medicine, March 2022, Elsevier

    Dr Eric Dannaoui

  11. Circulation of an Artemisinin-Resistant Malaria Lineage in a Traveler Returning from East Africa to France

    Article • Clinical Infectious Diseases, February 2022, Oxford University Press (OUP)

    Dr Eric Dannaoui

  12. Terbinafine Resistance in Dermatophytes: A French Multicenter Prospective Study

    Article • Journal of Fungi, February 2022, MDPI AG

    Dr Eric Dannaoui

  13. Antifungal Drugs TDM: Trends and Update

    Article • Therapeutic Drug Monitoring, February 2022, Wolters Kluwer Health

    Dr Eric Dannaoui

  14. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study

    Article • The Lancet Respiratory Medicine, February 2022, Elsevier

    Dr Eric Dannaoui

  15. In Vitro Activity of Amphotericin B in Combination with Colistin against Fungi Responsible for Invasive Infections

    Article • Journal of Fungi, January 2022, MDPI AG

    Dr Eric Dannaoui

  16. Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes

    Article • Journal of Antimicrobial Chemotherapy, January 2022, Oxford University Press (OUP)

    Dr Eric Dannaoui

  17. In Vitro Antifungal Combination of Terbinafine with Itraconazole against Isolates of Trichophyton Species

    Article • Antimicrobial Agents and Chemotherapy, January 2022, ASM Journals

    Dr Eric Dannaoui

  18. Extensive Dermatophytosis Caused by Terbinafine-Resistant Trichophyton indotineae, France

    Article • Emerging Infectious Diseases, January 2022, Centers for Disease Control and Prevention (CDC)

    Dr Eric Dannaoui

  19. Azole resistance in Aspergillus fumigatus isolates from respiratory specimens in Lyon University Hospitals, France: prevalence and mechanisms involved

    Article • International Journal of Antimicrobial Agents, December 2021, Elsevier

    Dr Eric Dannaoui

  20. In Vivo Efficacy of Voriconazole in a Galleria mellonella Model of Invasive Infection Due to Azole-Susceptible or Resistant Aspergillus fumigatus Isolates

    Article • Journal of Fungi, November 2021, MDPI AG

    Dr Eric Dannaoui

  21. Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent Candida spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability

    Article • Antimicrobial Agents and Chemotherapy, October 2021, ASM Journals

    Dr Eric Dannaoui

  22. Analysis of Microbiota and Mycobiota in Fungal Ball Rhinosinusitis: Specific Interaction between Aspergillus fumigatus and Haemophilus influenza?

    Article • Journal of Fungi, July 2021, MDPI AG

    Dr Eric Dannaoui

  23. A review of significance of Aspergillus detection in airways of ICU COVID‐19 patients

    Article • Mycoses, July 2021, Wiley

    Dr Eric Dannaoui

  24. Microsporidiosis after liver transplantation: A French nationwide retrospective study

    Article • Transplant Infectious Disease, June 2021, Wiley

    Dr Eric Dannaoui

  25. Azole Resistance in Clinical and Environmental Aspergillus Isolates from the French West Indies (Martinique)

    Article • Journal of Fungi, April 2021, MDPI AG

    Dr Eric Dannaoui

  26. Special Issue: Antifungal Agents Recently Approved or under Development

    Article • Journal of Fungi, March 2021, MDPI AG

    Dr Eric Dannaoui

  27. Galleria mellonella as a screening tool to study virulence factors of Aspergillus fumigatus

    Article • Virulence, March 2021, Taylor & Francis

    Dr Eric Dannaoui

  28. Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations

    Article • Journal of Fungi, February 2021, MDPI AG

    Dr Eric Dannaoui

  29. Plasmodium ovale wallikeri and P. ovale curtisi Infections and Diagnostic Approaches to Imported Malaria, France, 2013–2018

    Article • Emerging Infectious Diseases, February 2021, Centers for Disease Control and Prevention (CDC)

    Dr Eric Dannaoui

  30. Species distribution and antifungal susceptibility of Aspergillus clinical isolates in Lebanon

    Article • Future Microbiology, January 2021, Future Medicine

    Dr Eric Dannaoui

  31. MixInYeast: A Multicenter Study on Mixed Yeast Infections

    Article • Journal of Fungi, December 2020, MDPI AG

    Dr Eric Dannaoui

  32. In vitro synergy of isavuconazole in combination with colistin against Candida auris

    Article • Scientific Reports, December 2020, Springer Science + Business Media

    Dr Eric Dannaoui

  33. Modulated Response of Aspergillus fumigatus and Stenotrophomonas maltophilia to Antimicrobial Agents in Polymicrobial Biofilm

    Article • Frontiers in Cellular and Infection Microbiology, October 2020, Frontiers

    Dr Eric Dannaoui

  34. Colistin and Isavuconazole Interact Synergistically In Vitro against Aspergillus nidulans and Aspergillus niger

    Article • Microorganisms, September 2020, MDPI AG

    Dr Eric Dannaoui

  35. In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species

    Article • Journal of Fungi, July 2020, MDPI AG

    Dr Eric Dannaoui

  36. Candida albicans and Candida dubliniensis Show Different Trailing Effect Patterns When Exposed to Echinocandins and Azoles

    Article • Frontiers in Microbiology, June 2020, Frontiers

    Dr Eric Dannaoui

  37. Antifungal susceptibility testing practices in mycology laboratories in France, 2018

    Article • Journal de Mycologie Médicale, June 2020, Elsevier

    Dr Eric Dannaoui

  38. In vitro synergy of echinocandins with triazoles against fluconazole-resistant Candida parapsilosis complex isolates

    Article • Journal of Global Antimicrobial Resistance, June 2020, Elsevier

    Dr Eric Dannaoui

  39. Invasive fungal diseases during COVID-19: We should be prepared

    Article • Journal de Mycologie Médicale, June 2020, Elsevier

    Dr Eric Dannaoui

  40. Post-traumatic Curvularia sp. arthritis in an immunocompetent adult

    Article • Journal de Mycologie Médicale, June 2020, Elsevier

    Dr Eric Dannaoui

  41. Update on the diagnosis of parasitic and fungal infections

    Article • Annales de biologie clinique, June 2020, John Libbey Eurotext

    Dr Eric Dannaoui

  42. Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes

    Article • Journal of Antimicrobial Chemotherapy, April 2020, Oxford University Press (OUP)

    Dr Eric Dannaoui

  43. Galleria mellonella for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review

    Article • Microorganisms, March 2020, MDPI AG

    Dr Eric Dannaoui

  44. Invasive Aspergillosis Due to Aspergillus Section Usti: A Multicenter Retrospective Study

    Article • Clinical Infectious Diseases, March 2020, Oxford University Press (OUP)

    Dr Eric Dannaoui

  45. Colistin interacts synergistically with echinocandins against Candida auris

    Article • International Journal of Antimicrobial Agents, March 2020, Elsevier

    Dr Eric Dannaoui

  46. Comparison of the MICs Obtained by Gradient Concentration Strip and EUCAST Methods for Four Azole Drugs and Amphotericin B against Azole-Susceptible and -Resistant Aspergillus Section Fumigati ...

    Article • Antimicrobial Agents and Chemotherapy, February 2020, ASM Journals

    Dr Eric Dannaoui

  47. Should Etest MICs for Yeasts Be Categorized by Reference (BPs/ECVs) or by Etest (ECVs) Cutoffs as Determinants of Emerging Resistance?

    Article • Current Fungal Infection Reports, February 2020, Springer Science + Business Media

    Dr Eric Dannaoui

  48. Special Issue: Mucorales and Mucormycosis

    Article • Journal of Fungi, December 2019, MDPI AG

    Dr Eric Dannaoui

  49. In Vitro Antifungal Combination of Flucytosine with Amphotericin B, Voriconazole, or Micafungin against Candida auris Shows No Antagonism

    Article • Antimicrobial Agents and Chemotherapy, December 2019, ASM Journals

    Dr Eric Dannaoui

  50. Multicentre study to determine the Etest epidemiological cut-off values of antifungal drugs in Candida spp. and Aspergillus fumigatus species complex

    Article • Clinical Microbiology and Infection, December 2019, Elsevier

    Dr Eric Dannaoui

  51. Antifungal Susceptibly Testing by Concentration Gradient Strip Etest Method for Fungal Isolates: A Review

    Article • Journal of Fungi, November 2019, MDPI AG

    Dr Eric Dannaoui

  52. Indifferent effect of nonsteroidal anti-inflammatory drugs (NSAIDs) combined with fluconazole against multidrug-resistant Candida auris

    Article • Current Medical Mycology, November 2019, Negah Scientific Publisher

    Dr Eric Dannaoui, Dr Fatemeh Ahangarkani

  53. Evaluation of the Gradient Concentration Strip Method for Antifungal Susceptibility Testing of Isavuconazole and Comparators for Mucorales Species

    Article • Antimicrobial Agents and Chemotherapy, October 2019, ASM Journals

    Dr Eric Dannaoui

  54. Antifungal combinations in Mucorales: A microbiological perspective

    Article • Mycoses, July 2019, Wiley

    Dr Eric Dannaoui

  55. Identification of Mucorales by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry

    Article • Journal of Fungi, July 2019, MDPI AG

    Dr Eric Dannaoui

  56. In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales

    Article • Journal of Antimicrobial Chemotherapy, April 2019, Oxford University Press (OUP)

    Dr Eric Dannaoui

  57. Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study “MFIP”

    Article • Journal of Cystic Fibrosis, March 2019, Elsevier

    Dr Eric Dannaoui

  58. Aspergillus pseudodeflectus: a new human pathogen in liver transplant patients

    Article • BMC Infectious Diseases, December 2018, Springer Science + Business Media

    Dr Eric Dannaoui

  59. Interactions of Aspergillus fumigatus and Stenotrophomonas maltophilia in an in vitro Mixed Biofilm Model: Does the Strain Matter?

    Article • Frontiers in Microbiology, November 2018, Frontiers

    Dr Eric Dannaoui

  60. Occurrence and species diversity of human-pathogenic Mucorales in commercial food-stuffs purchased in Paris area

    Article • Medical Mycology, November 2018, Oxford University Press (OUP)

    Dr Eric Dannaoui

  61. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods

    Article • Antimicrobial Agents and Chemotherapy, October 2018, ASM Journals

    Professor Guillermo Quindós, Dr Eric Dannaoui

  62. Candida auris: An emerging drug resistant yeast – A mini-review

    Article • Journal de Mycologie Médicale, September 2018, Elsevier

    Dr Eric Dannaoui

  63. Human cryptosporidiosis in immunodeficient patients in France (2015–2017)

    Article • Experimental Parasitology, September 2018, Elsevier

    Dr Eric Dannaoui

  64. In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions

    Article • Diagnostic Microbiology and Infectious Disease, July 2018, Elsevier

    Dr Eric Dannaoui

  65. Comparative virulence of Candida auris with Candida haemulonii , Candida glabrata and Candida albicans in a murine model

    Article • Mycoses, March 2018, Wiley

    Dr Jacques F Meis, Dr Hamid Badali, Dr Eric Dannaoui

  66. Species Identification and In Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Clinical Isolates from a French Multicenter Study

    Article • Antimicrobial Agents and Chemotherapy, February 2018, ASM Journals

    Dr Eric Dannaoui, Pr Stephane Ranque

  67. Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values

    Article • Antimicrobial Agents and Chemotherapy, February 2018, ASM Journals

    Dr Eric Dannaoui

  68. In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex

    Article • Mycoses, November 2017, Wiley

    Dr Hamid Badali, Afsane Vaezi, Prof. Tahereh Shokohi, Dr Eric Dannaoui

  69. Population Structure of Candida parapsilosis: No Genetic Difference Between French and Uruguayan Isolates Using Microsatellite Length Polymorphism

    Article • Mycopathologia, November 2017, Springer Science + Business Media

    Dr Eric Dannaoui

  70. Antifungal resistance in mucorales

    Article • International Journal of Antimicrobial Agents, November 2017, Elsevier

    Dr Eric Dannaoui

  71. Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosis—The ESCAPE Study

    Article • Clinical Infectious Diseases, October 2017, Oxford University Press (OUP)

    Dr Eric Dannaoui

  72. In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.

    Article • Antimicrobial Agents and Chemotherapy, October 2017, ASM Journals

    Dr Eric Dannaoui

  73. PCR-based detection of Aspergillus fumigatus and absence of azole resistance due to TR34 /L98H in a french multicenter cohort of 137 patients with fungal rhinosinusitis

    Article • Mycoses, September 2017, Wiley

    Claire Cottrel, Dr Eric Dannaoui

  74. In Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris

    Article • Antimicrobial Agents and Chemotherapy, August 2017, ASM Journals

    Dr Hamid Badali, Dr Jacques F Meis, Dr Eric Dannaoui

  75. Molecular Diagnosis of Invasive Aspergillosis and Detection of Azole Resistance by a Newly Commercialized PCR Kit

    Article • Journal of Clinical Microbiology, August 2017, ASM Journals

    Dr Eric Dannaoui

  76. Clinical outcome of cystic fibrosis patients colonized by Scedosporium species following lung transplantation: A single-center 15-year experience

    Article • Transplant Infectious Disease, August 2017, Wiley

    Dr Eric Dannaoui

  77. Occurrence and species distribution of pathogenic Mucorales in unselected soil samples from France

    Article • Medical Mycology, July 2017, Oxford University Press (OUP)

    Dr Eric Dannaoui

  78. Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?

    Article • Mycopathologia, June 2017, Springer Science + Business Media

    Dr Eric Dannaoui

  79. Fatal Pulmonary Mucormycosis due to Rhizopus homothallicus

    Article • Mycopathologia, June 2017, Springer Science + Business Media

    Dr Eric Dannaoui

  80. Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002–14)

    Article • Journal of Antimicrobial Chemotherapy, March 2017, Oxford University Press (OUP)

    Dr Eric Dannaoui

  81. An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples

    Article • Journal of Chromatography B, March 2017, Elsevier

    Dr Eric Dannaoui

  82. Preferential expression of domain cassettes 4, 8 and 13 of Plasmodium falciparum erythrocyte membrane protein 1 in severe malaria imported in France

    Article • Clinical Microbiology and Infection, March 2017, Elsevier

    Dr Eric Dannaoui

  83. Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method

    Article • Antimicrobial Agents and Chemotherapy, January 2017, ASM Journals

    Dr Eric Dannaoui

  84. Characteristics of Aspergillus fumigatus in Association with Stenotrophomonas maltophilia in an In Vitro Model of Mixed Biofilm

    Article • PLoS ONE, November 2016, PLOS

    Dr Eric Dannaoui

  85. Echinocandin Resistance in Candida Species Isolates from Liver Transplant Recipients

    Article • Antimicrobial Agents and Chemotherapy, November 2016, ASM Journals

    Dr Eric Dannaoui

  86. Activities of Novel Azoles against Candida spp.

    Article • Antimicrobial Agents and Chemotherapy, October 2016, ASM Journals

    Dr Eric Dannaoui, Dr Hamid Badali

  87. Multicenter Comparison of the Etest and EUCAST Methods for Antifungal Susceptibility Testing of Candida Isolates to Micafungin

    Article • Antimicrobial Agents and Chemotherapy, June 2016, ASM Journals

    Dr Eric Dannaoui, Pr Stephane Ranque

  88. Reducing hypoxia and inflammation during invasive pulmonary aspergillosis by targeting the Interleukin-1 receptor

    Article • Scientific Reports, May 2016, Nature

    Dr Eric Dannaoui

  89. Novel Taxa Associated with Human Fungal Black-Grain Mycetomas: Emarellia grisea gen. nov., sp. nov., and Emarellia paragrisea sp. nov.

    Article • Journal of Clinical Microbiology, April 2016, ASM Journals

    Dr Eric Dannaoui, Andy Borman

  90. La résistance aux antifongiques : importance en médecine humaine et vétérinaire

    Article • Bulletin de l Académie vétérinaire de France, January 2016, INIST-CNRS

    Dr Eric Dannaoui

  91. Occurrence and species distribution of pathogenic Mucorales in unselected soil samples from France

    Article • Journal de Mycologie Médicale, September 2015, Elsevier

    Dr Eric Dannaoui

  92. Sensibilité des levures aux principaux antifongiques systémiques : intérêt du système Sensititre® Yeast One® et détermination des ECOFFs

    Article • Journal de Mycologie Médicale, June 2015, Elsevier

    Dr Eric Dannaoui

  93. Prospective Multicenter International Surveillance of Azole Resistance inAspergillus fumigatus

    Article • Emerging Infectious Diseases, June 2015, Centers for Disease Control and Prevention (CDC)

    Dr Eric Dannaoui

  94. Prospective evaluation of azole resistance inAspergillus fumigatusclinical isolates in France: Table 1.

    Article • Medical Mycology, May 2015, Oxford University Press (OUP)

    Dr Eric Dannaoui

  95. Next-generation sequencing offers new insights into the resistance of Candida spp. to echinocandins and azoles

    Article • Journal of Antimicrobial Chemotherapy, May 2015, Oxford University Press (OUP)

    Dr Eric Dannaoui

  96. In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp.

    Article • Journal of Medical Microbiology, March 2015, Society for General Microbiology

    Dr Eric Dannaoui

  97. Multicenter Evaluation of MIC Distributions for Epidemiologic Cutoff Value Definition To Detect Amphotericin B, Posaconazole, and Itraconazole Resistance among the Most Clinically Relevant Species of Mucorales

    Article • Antimicrobial Agents and Chemotherapy, January 2015, ASM Journals

    Dr Jacques F Meis, Dr Eric Dannaoui

  98. Molecular identification of fungi found on decomposed human bodies in forensic autopsy cases

    Article • International Journal of Legal Medicine, November 2014, Springer Science + Business Media

    Dr Eric Dannaoui

  99. In VitroCombination of Voriconazole and Miltefosine against Clinically Relevant Molds

    Article • Antimicrobial Agents and Chemotherapy, September 2014, ASM Journals

    Dr Eric Dannaoui

  100. Current Status of Diagnosis of Mucormycosis: Update on Molecular Methods

    Article • Current Fungal Infection Reports, August 2014, Springer Science + Business Media

    Dr Eric Dannaoui

  101. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010)

    Article • Intensive Care Medicine, August 2014, Springer Science + Business Media

    Dr Eric Dannaoui

  102. Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?

    Article • European Journal of Clinical Microbiology & Infectious Diseases, April 2014, Springer Science + Business Media

    Dr Eric Dannaoui

  103. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections

    Article • Clinical Microbiology and Infection, April 2014, Elsevier

    Dr Jacques F Meis, Dr Eric Dannaoui

  104. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others

    Article • Clinical Microbiology and Infection, April 2014, Elsevier

    Dr Eric Dannaoui, Dr Jacques F Meis

  105. ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013

    Article • Clinical Microbiology and Infection, April 2014, Elsevier

    Dr Eric Dannaoui, Dr Jacques F Meis

  106. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi

    Article • Clinical Microbiology and Infection, April 2014, Elsevier

    Dr Eric Dannaoui, Dr Jacques F Meis

  107. Mutations in the Cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus isolated from avian farms in France and China

    Article • Poultry Science, January 2014, Oxford University Press (OUP)

    Dr Eric Dannaoui

  108. Acremonium sclerotigenum-Acremonium egyptiacum: a multi-resistant fungal pathogen complicating the course of aplastic anaemia

    Article • Clinical Microbiology and Infection, January 2014, Elsevier

    Dr Eric Dannaoui

  109. Interlaboratory Variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST Methods: Should the Clinical Laboratory Be Testing This Agent?

    Article • Antimicrobial Agents and Chemotherapy, September 2013, ASM Journals

    Dr Jacques F Meis, Dr Eric Dannaoui

  110. Faculty of 1000 evaluation for Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients.

    Article • April 2013, Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  111. Résistance des Candida aux antifongiques : détection et mécanismes

    Article • Revue Francophone des Laboratoires, March 2013, Elsevier

    Dr Eric Dannaoui

  112. Définitions actuelles : « breakpoints-epidemiological cut-off »

    Article • Journal de Mycologie Médicale, March 2013, Elsevier

    Dr Eric Dannaoui

  113. Rapid Emergence of Echinocandin Resistance during Candida kefyr Fungemia Treatment with Caspofungin

    Article • Antimicrobial Agents and Chemotherapy, February 2013, ASM Journals

    Dr Eric Dannaoui

  114. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008)

    Article • Clinical Microbiology and Infection, October 2012, Elsevier

    Dr Eric Dannaoui

  115. Estimating the burden of mucormycosis infections in France (2005–2007) through a capture-recapture method on laboratory and administrative data

    Article • Revue d Épidémiologie et de Santé Publique, October 2012, Elsevier

    Dr Eric Dannaoui

  116. In VitroCombination of Anidulafungin and Voriconazole against Intrinsically Azole-Susceptible and -Resistant Aspergillus spp.

    Article • Antimicrobial Agents and Chemotherapy, May 2012, ASM Journals

    Alexandre Alanio, Dr Eric Dannaoui

  117. Healthcare-Associated Mucormycosis

    Article • Clinical Infectious Diseases, February 2012, Oxford University Press (OUP)

    Professor Marc Lecuit, Dr Eric Dannaoui

  118. A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007)

    Article • Clinical Infectious Diseases, January 2012, Oxford University Press (OUP)

    Dr Eric Dannaoui

  119. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia

    Article • Bone Marrow Transplantation, January 2012, Springer Science + Business Media

    Dr Eric Dannaoui

  120. Candida spp. with Acquired Echinocandin Resistance, France, 2004–20101

    Article • Emerging Infectious Diseases, January 2012, Centers for Disease Control and Prevention (CDC)

    Dr Eric Dannaoui

  121. Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales

    Article • Journal of Clinical Microbiology, November 2011, ASM Journals

    Dr Jacques F Meis, Dr Eric Dannaoui

  122. Imported Acquired Immunodeficiency Syndrome–Related Histoplasmosis in Metropolitan France: A Comparison of Pre–Highly Active Anti-Retroviral Therapy and Highly Active Anti-Retroviral Therapy Eras

    Article • American Journal of Tropical Medicine and Hygiene, November 2011, American Society of Tropical Medicine and Hygiene

    Dr Eric Dannaoui, Pr Stephane Ranque

  123. Prior Caspofungin Exposure in Patients with Hematological Malignancies Is a Risk Factor for Subsequent Fungemia Due to Decreased Susceptibility in Candida spp.: a Case-Control Study in Paris, France

    Article • Antimicrobial Agents and Chemotherapy, August 2011, ASM Journals

    Dr Eric Dannaoui

  124. Increased Mortality in Young Candidemia Patients Associated with Presence of a Candida albicans General-Purpose Genotype

    Article • Journal of Clinical Microbiology, July 2011, ASM Journals

    Dr Eric Dannaoui

  125. Saksenaea

    Article • June 2011, Taylor & Francis

    Dr Eric Dannaoui

  126. Faculty of 1000 evaluation for Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence.

    Article • February 2011, Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  127. Pneumocystosis: a network survey in the Paris area 2003–2008

    Article • European Journal of Clinical Microbiology & Infectious Diseases, January 2011, Springer Science + Business Media

    Dr Eric Dannaoui

  128. Agents of Systemic and Subcutaneous Mucormycosis and Entomophthoromycosis

    Article • January 2011, ASM Journals

    Dr Eric Dannaoui

  129. Mycétomes

    Article • January 2011, Elsevier

    Dr Eric Dannaoui

  130. ACKNOWLEDGEMENT OF REVIEWERS

    Article • Clinical Microbiology and Infection, January 2011, Elsevier

    Professor Martin M Rottman, Dr Eric Dannaoui

  131. Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 Patients

    Article • Antimicrobial Agents and Chemotherapy, November 2010, ASM Journals

    Dr Eric Dannaoui

  132. Comparison of antifungal MICs for yeasts obtained using the EU-CAST method in a reference laboratory and the Etest in nine different hospital laboratories

    Article • Clinical Microbiology and Infection, July 2010, Elsevier

    Dr Eric Dannaoui

  133. Geosmithia argillacea: an Emerging Pathogen in Patients with Cystic Fibrosis

    Article • Journal of Clinical Microbiology, May 2010, ASM Journals

    Dr Eric Dannaoui

  134. Molecular Detection and Identification of Zygomycetes Species from Paraffin-Embedded Tissues in a Murine Model of Disseminated Zygomycosis: a Collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Stud...

    Article • Journal of Clinical Microbiology, April 2010, ASM Journals

    Dr Eric Dannaoui

  135. Successful Triple Combination Therapy of Disseminated Absidia corymbifera Infection in an Adolescent With Osteosarcoma

    Article • Journal of Pediatric Hematology/Oncology, March 2010, Wolters Kluwer Health

    Dr Eric Dannaoui

  136. Associations antifongiques dans les infections fongiques invasives

    Article • La Revue de Médecine Interne, January 2010, Elsevier

    Dr Eric Dannaoui

  137. Réseau pneumocystose francilien : bilan de cinq années de surveillance (2003–2007)

    Article • Journal de Mycologie Médicale, December 2009, Elsevier

    Dr Eric Dannaoui

  138. Molecular and Phenotypic Evaluation of Lichtheimia corymbifera (Formerly Absidia corymbifera) Complex Isolates Associated with Human Mucormycosis: Rehabilitation of L. ramosa

    Article • Journal of Clinical Microbiology, September 2009, ASM Journals

    Dr Eric Dannaoui

  139. Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006

    Article • Emerging Infectious Diseases, September 2009, Centers for Disease Control and Prevention (CDC)

    Dr Eric Dannaoui

  140. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients

    Article • Transplant Infectious Disease, June 2009, Wiley

    Dr Eric Dannaoui

  141. In Vitro Interactions between Antifungals and Immunosuppressive Drugs against Zygomycetes

    Article • Antimicrobial Agents and Chemotherapy, May 2009, ASM Journals

    Dr Eric Dannaoui

  142. Isolement d’ Exophiala dermatitidis dans des prélèvements d’origine pulmonaire : à propos de six patients

    Article • Journal de Mycologie Médicale, March 2009, Elsevier

    Dr Eric Dannaoui, Pr Stephane Ranque

  143. An increasing trend of cutaneous zygomycosis caused byMycocladus corymbifer(formerlyAbsidia corymbifera): report of two cases and review of primary cutaneousMycocladusinfections

    Article • Medical Mycology, January 2009, Oxford University Press (OUP)

    Dr Eric Dannaoui

  144. Errata

    Article • Clinical Microbiology and Infection, January 2009, Elsevier

    Dr Eric Dannaoui

  145. Errata

    Article • Clinical Microbiology and Infection, January 2009, Elsevier

    Dr Eric Dannaoui

  146. Errata

    Article • Clinical Microbiology and Infection, January 2009, Elsevier

    Dr Eric Dannaoui

  147. Molecular tools for identification of Zygomycetes and the diagnosis of zygomycosis

    Article • Clinical Microbiology and Infection, January 2009, Elsevier

    Dr Eric Dannaoui

  148. Sequence-Based Identification of Aspergillus, Fusarium, and Mucorales Species in the Clinical Mycology Laboratory: Where Are We and Where Should We Go from Here?

    Article • Journal of Clinical Microbiology, December 2008, ASM Journals

    Dr Eric Dannaoui

  149. EUCAST Technical Note on voriconazole

    Article • Clinical Microbiology and Infection, October 2008, Elsevier

    Dr Eric Dannaoui

  150. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming moulds

    Article • Clinical Microbiology and Infection, October 2008, Elsevier

    Dr Eric Dannaoui

  151. Molecular Diagnosis of Saksenaea vasiformis Cutaneous Infection after Scorpion Sting in an Immunocompetent Adolescent

    Article • Journal of Clinical Microbiology, July 2008, ASM Journals

    Dr Eric Dannaoui

  152. Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing

    Article • Antimicrobial Agents and Chemotherapy, June 2008, ASM Journals

    Dr Eric Dannaoui

  153. Coccidioïdomycose : une maladie d’importation d’actualité en France

    Article • Médecine et Maladies Infectieuses, June 2008, Elsevier

    Dr Eric Dannaoui

  154. Une maladie d’importation

    Article • Médecine et Maladies Infectieuses, June 2008, Elsevier

    Dr Eric Dannaoui

  155. Lack of evidence of endosymbiotic toxin-producing bacteria in clinical Rhizopus isolates

    Article • Mycoses, May 2008, Wiley

    Dr Eric Dannaoui

  156. Associations antifongiques dans les candidoses et aspergilloses invasives

    Article • Réanimation, May 2008, Elsevier

    Dr Eric Dannaoui

  157. Detection of Caspofungin Resistance in Candida spp. by Etest

    Article • Journal of Clinical Microbiology, April 2008, ASM Journals

    Dr Eric Dannaoui

  158. Clonal Population of Flucytosine-ResistantCandida tropicalisfrom Blood Cultures, Paris, France

    Article • Emerging Infectious Diseases, April 2008, Centers for Disease Control and Prevention (CDC)

    Dr Eric Dannaoui

  159. Saksenaea vasiformis Infection, French Guiana

    Article • Emerging Infectious Diseases, February 2008, Centers for Disease Control and Prevention (CDC)

    Dr Eric Dannaoui

  160. EUCAST Technical Note on fluconazole

    Article • Clinical Microbiology and Infection, February 2008, Elsevier

    Dr Eric Dannaoui

  161. Failure of Deferasirox, an Iron Chelator Agent, Combined with Antifungals in a Case of Severe Zygomycosis

    Article • Antimicrobial Agents and Chemotherapy, January 2008, ASM Journals

    Dr Eric Dannaoui

  162. Comparative In Vitro Activities of Caspofungin and Micafungin, Determined Using the Method of the European Committee on Antimicrobial Susceptibility Testing, against Yeast Isolates Obtained in France in 2005-2006

    Article • Antimicrobial Agents and Chemotherapy, December 2007, ASM Journals

    Dr Eric Dannaoui

  163. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on A...

    Article • Clinical Microbiology and Infection, October 2007, Elsevier

    Dr Eric Dannaoui

  164. In Vitro Susceptibility to Posaconazole of 1,903 Yeast Isolates Recovered in France from 2003 to 2006 and Tested by the Method of the European Committee on Antimicrobial Susceptibility Testing

    Article • Antimicrobial Agents and Chemotherapy, June 2007, ASM Journals

    Dr Eric Dannaoui

  165. Acquired resistance to echinocandins in Candida albicans: case report and review

    Article • Journal of Antimicrobial Chemotherapy, April 2007, Oxford University Press (OUP)

    Dr Eric Dannaoui

  166. Carbon Assimilation Profiles as a Tool for Identification of Zygomycetes

    Article • Journal of Clinical Microbiology, February 2007, ASM Journals

    Dr Eric Dannaoui

  167. Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study

    Article • PLoS Medicine, February 2007, PLOS

    Dr Eric Dannaoui

  168. The Zygomycetes

    Article • January 2007, Springer Science + Business Media

    Dr Eric Dannaoui

  169. Pneumocystosis: Survey and DHPS Genotype Analysis in 14 Parisian Hospitals in 2003 and 2004

    Article • Journal of Eukaryotic Microbiology, November 2006, Wiley

    Dr Eric Dannaoui

  170. Combination of Amphotericin B with Flucytosine Is Active In Vitro against Flucytosine-Resistant Isolates of Cryptococcus neoformans

    Article • Antimicrobial Agents and Chemotherapy, October 2006, ASM Journals

    Dr Eric Dannaoui

  171. Molecular Identification of Black-Grain Mycetoma Agents

    Article • Journal of Clinical Microbiology, October 2006, ASM Journals

    Dr Eric Dannaoui

  172. Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus

    Article • Journal of Medical Microbiology, October 2006, Society for General Microbiology

    Dr Eric Dannaoui

  173. Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with Cryptococcosis

    Article • Antimicrobial Agents and Chemotherapy, July 2006, ASM Journals

    Dr Eric Dannaoui

  174. Méthodologie d’évaluation de la sensibilité in vitro aux antifongiques

    Article • Therapies, May 2006, Elsevier

    Dr Eric Dannaoui

  175. Molecular Identification of Zygomycetes from Culture and Experimentally Infected Tissues

    Article • Journal of Clinical Microbiology, February 2006, ASM Journals

    Dr Eric Dannaoui

  176. Efficacy of Amphotericin B in Combination with Flucytosine against Flucytosine-Susceptible or Flucytosine-Resistant Isolates of Cryptococcus neoformans during Disseminated Murine Cryptococcosis

    Article • Antimicrobial Agents and Chemotherapy, January 2006, ASM Journals

    Dr Eric Dannaoui

  177. In Vitro Evaluation of Double and Triple Combinations of Antifungal Drugs against Aspergillus fumigatus and Aspergillus terreus

    Article • Antimicrobial Agents and Chemotherapy, March 2004, ASM Journals

    Dr Eric Dannaoui

  178. Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients

    Article • Journal of Medical Microbiology, February 2004, Society for General Microbiology

    Dr Eric Dannaoui

  179. Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis

    Article • Antimicrobial Agents and Chemotherapy, November 2003, ASM Journals

    Dr Jacques F Meis, Dr Eric Dannaoui

  180. In Vitro Interaction of Flucytosine with Conventional and New Antifungals against Cryptococcus neoformans Clinical Isolates

    Article • Antimicrobial Agents and Chemotherapy, October 2003, ASM Journals

    Dr Eric Dannaoui

  181. Invasive Infections Due to Apophysomyces elegans

    Article • Mayo Clinic Proceedings, February 2003, Elsevier

    Dr Eric Dannaoui

  182. Evaluation of different commercial ELISA methods for the serodiagnosis of systemic candidosis

    Article • Mycoses, December 2002, Wiley

    Dr Eric Dannaoui

  183. In vitro susceptibilities of zygomycetes to conventional and new antifungals

    Article • Journal of Antimicrobial Chemotherapy, November 2002, Oxford University Press (OUP)

    Dr Jacques F Meis, Dr Eric Dannaoui

  184. In Vitro Synergistic Interaction between Amphotericin B and Pentamidine against Scedosporium prolificans

    Article • Antimicrobial Agents and Chemotherapy, October 2002, ASM Journals

    Dr Jacques F Meis, Dr Eric Dannaoui

  185. In Vitro Susceptibilities of Zygomycetes to Combinations of Antimicrobial Agents

    Article • Antimicrobial Agents and Chemotherapy, August 2002, ASM Journals

    Dr Jacques F Meis, Dr Eric Dannaoui

  186. Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis

    Article • Antimicrobial Agents and Chemotherapy, June 2002, ASM Journals

    Dr Jacques F Meis, Dr Eric Dannaoui

  187. In vitro susceptibilities of Zygomycota to polyenes

    Article • Journal of Antimicrobial Chemotherapy, May 2002, Oxford University Press (OUP)

    Dr Eric Dannaoui

  188. Effect of Medium Composition on Static and Cidal Activity of Amphotericin B, Itraconazole, Voriconazole, Posaconazole and Terbinafine AgainstAspergillus fumigatus:A Multicenter Study

    Article • Journal of Chemotherapy, January 2002, Taylor & Francis

    Dr Eric Dannaoui

  189. Sterol composition of itraconazole-resistant and itraconazole-susceptible isolates of Aspergillus fumigatus

    Article • Canadian Journal of Microbiology, August 2001, Canadian Science Publishing

    Dr Eric Dannaoui

  190. Acquired itraconazole resistance in Aspergillus fumigatus

    Article • Journal of Antimicrobial Chemotherapy, March 2001, Oxford University Press (OUP)

    Dr Eric Dannaoui

  191. Sterol composition of itraconazole-resistant and itraconazole-susceptible isolates of Aspergillus fumigatus

    Article • Canadian Journal of Microbiology, January 2001, Canadian Science Publishing

    Dr Eric Dannaoui

  192. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis

    Article • Journal of Medical Microbiology, July 2000, Society for General Microbiology

    Dr Eric Dannaoui

  193. In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis

    Article • Journal of Medical Microbiology, December 1999, Society for General Microbiology

    Dr Eric Dannaoui

  194. Use of spectrophotometric reading for in vitro antifungal susceptibility testing of Aspergillus spp.

    Article • Canadian Journal of Microbiology, October 1999, Canadian Science Publishing

    Dr Eric Dannaoui

  195. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole

    Article • Journal of Antimicrobial Chemotherapy, October 1999, Oxford University Press (OUP)

    Dr Eric Dannaoui

  196. Early Microascus cinereus Endocarditis of a Prosthetic Valve Implanted after Staphylococcus aureus Endocarditis of the Native Valve

    Article • Clinical Infectious Diseases, September 1999, Oxford University Press (OUP)

    Dr Eric Dannaoui

  197. Use of spectrophotometric reading for in vitro antifungal susceptibility testing of Aspergillus spp.

    Article • Canadian Journal of Microbiology, January 1999, Canadian Science Publishing

    Dr Eric Dannaoui

  198. Fluconazole susceptibility ofCandidaisolates from oropharyngeal candidosis

    Article • Mycoses, November 1997, Wiley

    Dr Eric Dannaoui

  199. Detection of Pneumocystis carinii DNA by PCR amplification in various rat organs in experimental pneumocystosis

    Article • Journal of Medical Microbiology, August 1997, Society for General Microbiology

    Dr Eric Dannaoui

  200. Evaluation of the E test for fluconazole susceptibility testing ofCandida albicans isolates from oropharyngeal candidiasis

    Article • European Journal of Clinical Microbiology & Infectious Diseases, March 1997, Springer Science + Business Media

    Dr Eric Dannaoui

  201. Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription

    Article • Antiviral Chemistry and Chemotherapy, February 1997, SAGE Publications

    Dr Eric Dannaoui

  202. Animal Models for Evaluation of Antifungal Efficacy Against Filamentous Fungi

    Article • Wiley

    Dr Eric Dannaoui

  203. Antifungal Combinations

    Article • Springer Science + Business Media

    Dr Eric Dannaoui

  204. Faculty of 1000 evaluation for Mucormycosis outbreak associated with hospital linens.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  205. Faculty of 1000 evaluation for Environmental Isolates of Azole-Resistant Aspergillus fumigatus in Germany.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  206. Faculty of 1000 evaluation for Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  207. Faculty of 1000 evaluation for Molecular methods to improve diagnosis and identification of mucormycosis.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  208. Faculty of 1000 evaluation for Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  209. Faculty of 1000 evaluation for Azole-resistant Aspergillus fumigatus in the environment of northern Italy, May 2011 to June 2012.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  210. Faculty of 1000 evaluation for Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  211. Faculty of 1000 evaluation for Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  212. Faculty of 1000 evaluation for Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  213. Faculty of 1000 evaluation for Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  214. Faculty of 1000 evaluation for The T788G mutation in the cyp51C gene confers voriconazole resistance in Aspergillus flavus causing aspergillosis.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  215. Faculty of 1000 evaluation for In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  216. Faculty of 1000 evaluation for Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometry.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui

  217. Faculty of 1000 evaluation for Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives.

    Article • Faculty of 1000, Ltd.

    Dr Eric Dannaoui